Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $56.3333.

Several research analysts have recently issued reports on the company. Bank of America cut their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Scotiabank cut their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research note on Monday, July 28th. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 19th.

Insider Transactions at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 18,700 shares of the company’s stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $627,198.00. Following the completion of the transaction, the chief executive officer owned 105,401 shares of the company’s stock, valued at $3,535,149.54. This represents a 15.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James William Burns sold 2,799 shares of the company’s stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $93,878.46. Following the transaction, the insider directly owned 28,650 shares of the company’s stock, valued at approximately $960,921. This represents a 8.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,448 shares of company stock worth $2,026,141 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. Wells Fargo & Company MN increased its stake in shares of Agios Pharmaceuticals by 184.9% during the 4th quarter. Wells Fargo & Company MN now owns 34,808 shares of the biopharmaceutical company’s stock valued at $1,144,000 after acquiring an additional 75,800 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Agios Pharmaceuticals by 3.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company’s stock worth $815,000 after purchasing an additional 795 shares during the period. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,587 shares during the period. Summit Investment Advisors Inc. grew its holdings in shares of Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 394 shares during the period. Finally, XTX Topco Ltd grew its holdings in shares of Agios Pharmaceuticals by 11.3% during the 4th quarter. XTX Topco Ltd now owns 9,272 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 943 shares during the period.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $37.01 on Monday. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58. The business has a fifty day moving average of $36.50 and a two-hundred day moving average of $32.76. The company has a market cap of $2.15 billion, a P/E ratio of 3.36 and a beta of 0.80.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Sell-side analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.